Back |
home / stock / imtx / imtx message board
Subject | By | Source | When |
---|---|---|---|
I hope so,... and turning back to accumulation | FACT-MASTER | investorshub | 10/03/2022 1:14:21 AM |
Looks a little like consolidation is over.... | Solarfuture | investorshub | 09/30/2022 6:48:05 PM |
Tracking Baker Bros. portfolio - $IMTX | FACT-MASTER | investorshub | 09/30/2022 1:37:47 AM |
Link to clinical trials here: | FACT-MASTER | investorshub | 09/27/2022 10:22:37 PM |
$IMTX Pipeline for review: | FACT-MASTER | investorshub | 09/26/2022 1:59:39 AM |
Just doing some review of 1Q/22 report here: | FACT-MASTER | investorshub | 09/26/2022 1:33:36 AM |
Of INTEREST: | FACT-MASTER | investorshub | 09/21/2022 11:35:19 PM |
Not looking good here - $IMTX | FACT-MASTER | investorshub | 09/21/2022 9:17:22 PM |
Thank u! | Solarfuture | investorshub | 09/15/2022 11:27:47 AM |
Geulah Livshits maintains her "strong buy" rating on Immatics. | FACT-MASTER | investorshub | 09/14/2022 9:21:57 PM |
Yes, I think so, too. I saw the | Solarfuture | investorshub | 09/13/2022 5:49:11 AM |
I've ruled out a "capital raise",imo, as | FACT-MASTER | investorshub | 09/13/2022 12:25:49 AM |
Today not really to understand, but good chance | Solarfuture | investorshub | 09/12/2022 2:44:13 PM |
Thank you! I have read it.I totally agree. | Solarfuture | investorshub | 09/12/2022 6:56:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...